Program
ABP-671
A development code. Also written as “ABP-671 plus allopurinol” and “ABP-671 Group”.
Its studies are mostly in Gout · Renal Insufficiency, Chronic · Hyperuricemia, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Atom Therapeutics | 41 open or running | phase 3since Apr 5, 2023 | Apr 5, 2023 | Oct 31, 2027phase 2 · NCT07323095 |
| Jiangsu Atom Bioscience and Pharmaceutical | 40 open or running | phase 2since Nov 16, 2020 | Apr 4, 2019 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 4, 2019First study: phase 1 study in GoutNew to Jiangsu Atom Bioscience and PharmaceuticalJiangsu Atom Bioscience and Pharmaceutical · NCT03906006 · 32 enrolled · United States
- Aug 15, 2019Phase 1 study in HyperuricemiaJiangsu Atom Bioscience and Pharmaceutical · NCT04060173 · 27 enrolled · United States
- Mar 6, 2020Phase 1 study in GoutJiangsu Atom Bioscience and Pharmaceutical · NCT04303039 · 12 enrolled · United States
- Nov 16, 2020Phase 2 study in GoutJiangsu Atom Bioscience and Pharmaceutical · NCT04638543 · 60 enrolled · Australia
- Apr 5, 2023Atom Therapeutics's first study: phase 3 study in GoutNew to Atom TherapeuticsAtom Therapeutics · NCT05818085 · 300 enrolled · United States, Australia, Georgia and more
- Feb 12, 2024Phase 3 study in GoutAtom Therapeutics · NCT06276556 · 43 enrolled · United States, Australia, Georgia and more
- Dec 8, 2025Phase 2 study in Renal Insufficiency, ChronicAtom Therapeutics · NCT07323095 · 80 planned · Australia, China
- Dec 27, 2025Phase 1 study in GoutAtom Therapeutics · NCT07367971 · 22 enrolled · United States
Ahead
- Oct 31, 2027Primary completion: phase 2 study in Renal Insufficiency, ChronicAtom Therapeutics · NCT07323095
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07367971Gout · United States | 1 | Completed | Atom Therapeutics | Aug 19, 2026 | 22 |
| NCT07323095Renal Insufficiency, Chronic · Australia, China | 2 | Recruiting | Atom Therapeutics | Oct 31, 2027 | 80 |
| NCT06276556Gout · United States, Australia, Georgia and more | 3 | Terminated | Atom Therapeutics | Sep 5, 2024 | 43 |
| NCT05818085Gout · United States, Australia, Georgia and more | 3 | Completed | Atom Therapeutics | Jan 30, 2025 | 300 |
| NCT04638543Gout · Australia | 2 | Completed | Jiangsu Atom Bioscience and Pharmaceutical | Oct 26, 2021 | 60 |
| NCT04303039Gout · United States | 1 | Completed | Jiangsu Atom Bioscience and Pharmaceutical | Jun 9, 2020 | 12 |
| NCT04060173Hyperuricemia · United States | 1 | Completed | Jiangsu Atom Bioscience and Pharmaceutical | Dec 29, 2019 | 27 |
| NCT03906006Gout · United States | 1 | Completed | Jiangsu Atom Bioscience and Pharmaceutical | Jun 20, 2019 | 32 |
How it is read
Names in the registry
- “ABP-671”, 6 entries
- “ABP-671 plus allopurinol”, 1 entry
- “ABP-671 Group”, 1 entry
Codes read as this program: ABP671.
Conditions, from the studies’ own filings
- Gout, 6 studies
- Renal Insufficiency, Chronic, 1 study
- Hyperuricemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.